Furey Raymond J. 4
4 · RIGEL PHARMACEUTICALS INC · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Rigel (RIGL) EVP Raymond J. Furey Receives Stock Award (7,394)
What Happened
Raymond J. Furey, EVP, General Counsel, Chief Compliance Officer & Corporate Secretary of Rigel Pharmaceuticals (RIGL), reported a derivative award: 7,394 shares became vested on June 17, 2026. The filing lists the acquisition as $0 because this was the vesting of a performance-based option (not a cash purchase). The option's exercise price is $22.49 per share, implying approximately $166,291 required to exercise all options.
Key Details
- Transaction date: June 17, 2026 (grant/vesting of a performance-based option)
- Report filed: June 22, 2026 (Form 4 — filing was late relative to the usual 2-business-day rule)
- Shares involved: 7,394 derivative shares (optioned)
- Exercise price: $22.49 per share (equal to closing price on original grant date, Jan 29, 2025)
- Shares owned after transaction: Not specified in the provided filing
- Footnotes: (F1) Option originally granted Jan 29, 2025; not reportable until performance condition satisfied. (F2) The option fully vested on June 17, 2026 when the performance metric was met.
Context
This transaction reflects a performance-based option vesting (an award becoming exercisable), not an open-market purchase or sale. No immediate sale or exercise was reported — the option is now vested and can be exercised in the future subject to its terms. Vesting awards are common compensation events and do not by themselves indicate the insider bought or sold stock.
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1][F2]2026-06-17+7,394→ 7,394 totalExercise: $22.49Exp: 2035-01-29→ Common Stock (7,394 underlying)
Footnotes (2)
- [F1]The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- [F2]The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.